Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721248 · ClinicalTrials.gov registry record · Phase 2
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 13
- Study locations
NCT05721248 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 82 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT05721248, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Conditions Studied
Interventions
- OTHER Cessation of anti-HER2 treatment
Study Locations (13)
Massachusetts
- Dana-Farber Cancer Insitute - Boston
- DFCI @ Foxborough - Foxborough
- DFCI @ Merrimack Valley - Methuen
- DFCI @ Milford Regional Hospital - Milford
- DFCI @ South Shore Hospital - South Weymouth
Arizona
- Mayo Clinic Hospital Arizona - Phoenix
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Mayo Clinical Hospital Florida - Jacksonville
Minnesota
- Mayo Clinic Rochester - Rochester
North Carolina
- Duke University - Durham
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2036-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05721248
The ClinicalTrials.gov registry entry for NCT05721248 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cessation of anti-HER2 treatment is the first listed.
NCT05721248 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, Arizona, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05721248 about?
NCT05721248 is a clinical study titled "STOP-HER2: Stopping Trastuzumab in HER2+ MBC". This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting an...
What is the current status of trial NCT05721248?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-04-19. Estimated completion is 2036-06.
What conditions does trial NCT05721248 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT05721248?
The interventions under investigation include: Cessation of anti-HER2 treatment (OTHER).
Who is sponsoring clinical trial NCT05721248?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05721248 being conducted?
This trial has 13 study locations across Arizona, District of Columbia, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.